StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Offering Excerpt regarding receiving the Maximum amount

<< Previous

Bullboard Posts

Next >>

Comment by Jonnyboy85on Oct 19, 2020 5:44pm

128 Views

Post# 31745318

RE:RE:Offering Excerpt regarding receiving the Maximum amount

Almost missed that, love the expansion plans we're seeing

2020oilgamble wrote: Note as well.... 950,000 and 600,000 for these two items

Jonnyboy85 wrote: The final amount raised in the Offering will determine the speed at which each of the Company’s business milestones may be achieved. Assuming the completion of the Maximum Offering, the Company intends to: (i) pay the salaries and benefits for current employees for one year (approximately $3,330,000 in costs, $2,250,000 of which is expected to be paid from existing cash on hand), (ii) hire twenty-four (24) additional full-time employees to enhance lab testing capabilities and sales (instead of twelve (12) full-time employees under the Minimum Offering scenario) to enhance lab testing capabilities and sales (approximately $2,670,000 in costs, $nil of which is expected to be paid from existing cash on hand); (iii) purchase equipment, testing reagents and consumable materials for COVID-19 testing and Aristotle® development and sale (approximately $1,900,000 in costs, $nil of which is expected to be paid from existing cash on hand); (iv) pay for corporate marketing expenses for current products including COVID-19 and Aristotle® testing (approximately $3,000,000 in costs, $nil of which is expected to be paid from existing cash on hand); and (v) expand the Richmond Laboratory by approximately 5,000 square feet (approximately $180,000 in costs, $nil of which is expected to be paid from existing cash on hand). In addition to these testing capability enhancements, the Company intends to use a portion of the net proceeds of the Offering for working capital and general corporate purposes.